Emory University School of Medicine, Atlanta, GA, USA.
Center for Diabetes Metabolism Research, Emory University Hospital Midtown, Atlanta, GA, USA.
J Diabetes Sci Technol. 2024 Jul;18(4):974-987. doi: 10.1177/19322968221144052. Epub 2022 Dec 16.
Numerous studies have demonstrated the clinical value of continuous glucose monitoring (CGM) in type 1 diabetes (T1D) and type 2 diabetes (T2D) populations. However, the eligibility criteria for CGM coverage required by the Centers for Medicare & Medicaid Services (CMS) ignore the conclusive evidence that supports CGM use in various diabetes populations that are currently deemed ineligible. In an earlier article, we discussed the limitations and inconsistencies of the agency's CGM eligibility criteria relative to current scientific evidence and proposed practice solutions to address this issue and improve the safety and care of Medicare beneficiaries with diabetes. Although Medicaid is administered through CMS, there is no consistent Medicaid policy for CGM coverage in the United States. This article presents a rationale for modifying and standardizing Medicaid CGM coverage eligibility across the United States.
许多研究已经证明了连续血糖监测(CGM)在 1 型糖尿病(T1D)和 2 型糖尿病(T2D)患者中的临床价值。然而,医疗保险和医疗补助服务中心(CMS)规定的 CGM 覆盖范围的资格标准忽略了支持在各种目前被认为不合格的糖尿病患者中使用 CGM 的确凿证据。在之前的一篇文章中,我们讨论了该机构的 CGM 资格标准相对于当前科学证据的局限性和不一致性,并提出了一些实践解决方案来解决这个问题,以提高医疗保险糖尿病受益人的安全性和护理水平。尽管医疗补助是通过 CMS 管理的,但美国各州对 CGM 覆盖范围的医疗补助政策并不统一。本文提出了一个在美国修改和统一医疗补助 CGM 覆盖范围资格的理由。